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Abstract
Background: Malaria continues to be a devastating parasitic disease that causes the death of 2 million individuals annually.
The increase in multi-drug resistance together with the absence of an efficient vaccine hastens the need for speedy and
comprehensive antimalarial drug discovery and development. Throughout history, traditional herbal remedies or natural
products have been a reliable source of antimalarial agents, e.g. quinine and artemisinin. Today, one emerging source of
small molecule drug leads is the world’s oceans. Included among the source of marine natural products are marine
microorganisms such as the recently described actinomycete. Members of the genus Salinispora have yielded a wealth of
new secondary metabolites including salinosporamide A, a molecule currently advancing through clinical trials as an
anticancer agent. Because of the biological activity of metabolites being isolated from marine microorganisms, our group
became interested in exploring the potential efficacy of these compounds against the malaria parasite.
Methods: We screened 80 bacterial crude extracts for their activity against malaria growth. We established that the pure
compound, salinosporamide A, produced by the marine actinomycete, Salinispora tropica, shows strong inhibitory activity
against the erythrocytic stages of the parasite cycle. Biochemical experiments support the likely inhibition of the parasite
20S proteasome. Crystal structure modeling of salinosporamide A and the parasite catalytic 20S subunit further confirm this
hypothesis. Ultimately we showed that salinosporamide A protected mice against deadly malaria infection when
administered at an extremely low dosage.
Conclusion: These findings underline the potential of secondary metabolites, derived from marine microorganisms, to inhibit
Plasmodium growth. More specifically, we highlight the effect of proteasome inhibitors such as salinosporamide A on in vitro
and in vivo parasite development. Salinosporamide A (NPI-0052) now being advanced to phase I trials for the treatment of
refractory multiple myeloma will need to be further explored to evaluate the safety profile for its use against malaria.
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Introduction
Throughout history, secondary metabolites (natural products)
have provided a fundamental source of drugs for fighting infection,
inflammation and cancer in humans. In the case of malaria,
leveraging biodiversity in the natural environment has been one of
the most effective ways of combating the disease. Quinine was
extracted from the bark of a Peruvian Cinchona tree more than 350
years ago. It has been the most widely used drug until 1944 at which
time it was replace by chloroquine that was successfully synthesized
in 1934. The herb Artemisia annua, utilized by the Chinese to cure
malaria for more than 2000 years, is the source of the antimalarial,
artemisinin. Despite intense research, there is no doubt that plant-
derived compounds have outlived many of the synthetic drugs.
Although artemisinin provides efficacy, recent studies have
detected the emergence of drug resistance in the rodent malaria,
Plasmodium yoelii [1,2]. Drug resistances in the human malaria
parasite, P. falciparum, were also observed in vitro [3]. Recently,
artemisinin combinatorial therapy failures have been observed in
Cambodian patients [4]. Because of the constant emergence of
resistant strains and the absence of effective vaccines, there is a
pressing need to rapidly discover new cost-effective molecules
against the malaria parasite, which continues to kill 1.5 to 3 million
people each year.
Constituting more than 70% of the earth’s surface, our oceans
emerge as one of the greatest sources of biodiversity for the
discovery of natural products. Marine plants and invertebrates
have received much attention as a source of human therapeutics.
For example, a number of kinase inhibitors such as hymenialdisine
(HMD), a sponge-derived natural product with nanomolar activity
against several human kinases, have garnered much attention from
pharmaceutical companies [5]. Today several marine-derived
compounds used as anticancer agents are undergoing promising
preclinical and clinical development [6]. Although no marine
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malaria research community has a long-standing interest in
assessing marine derived compounds as new chemotherapies
against malaria. Molecules such as hymenialdisine and xestoqui-
none, both extracted from marine sponges, strongly inhibit
Plasmodium growth and Plasmodium-derived kinases [7,8,9,10].
These promising results have led to the conclusion that kinase
inhibitors represent a suitable chemotherapy against the malaria
parasite. Another promising antimalarial agent derived from a
marine sponge is manzamine A [11]. It has been proposed that the
true source of this alkaloid is a symbiotic bacterium living within
the sponge tissues (United States Patent Application
20050244938), thus providing opportunities for a renewable
supply of the compound without harvesting large quantities of
the sponge from nature.
Today, the microorganisms residing in deep ocean sediments
remain an untapped resource for natural compound discovery.
Included among these microorganisms are actinomycetes, a group
of bacteria that accounts for more than 50% of the antibiotics
identified to date [12]. These sediment-derived actinomycetes
include obligate marine taxa [13], and an impressive array of
readily cultivable diversity that has not been previously reported
from land [14]. In the past few years, chemical studies on marine
actinomycetes have yielded numerous novel secondary metabolites
that display a wide range of activity against human tumors and
other disease targets [15]. However, to our knowledge, none of
these compounds have been tested against parasitic diseases. We
therefore decided to test the ability of extracts from marine
sediment-derived actinomycetes to inhibit the human malaria
parasite, P. falciparum.
Our laboratory employed an adapted SYBR Green assay in
microplate format to screen a set of crude extracts from marine
microorganisms for their ability to inhibit parasite growth in
culture. One extract from the marine actinomycete, Salinispora
tropica, was selected for its high potency against parasite growth.
Pure active compounds from Salinispora tropica had been previously
identified and exhibited inhibitory effects in many human
malignant cell types [16,17,18,19]. Salinosporamide A, was
identified as a potent inhibitor of dividing melanoma cells and
showed a unique ability to inhibit the proteolytic activity of the
20S proteasome subunit without affecting any other proteases
[20,21]. The encouraging preclinical properties of this compound
and its entry into clinical trials phase I (Nereus Pharmaceuticals)
[22] motivated us to investigate further this orally active
proteasome inhibitor against Plasmodium. We first tested the effect
of pure salinosporamide A on parasite culture in vitro. The
compound showed strong growth inhibition with an IC50 in the
low sub-micromolar range (11.4 nM). At the phenotypic level, we
identified an arrest of the parasite’s progression during all
erythrocytic stages. In addition, we detected an increase of
ubiquitin conjugate proteins in parasite extracts after incubation
with the drug. Similar results were obtained with the well-defined
proteasome inhibitor MG-132 and lead us to conclude that the
parasite proteasome was the likely target of salinosporamide A.
Sequence comparisons and crystal structure modeling between
salinosporamide A and yeast, human and Plasmodium 20S
proteasome subunits further confirmed this potential target in
the parasite. We then defined the efficiency of the compound in a
malaria mouse model and found that the compound inhibited
parasite growth and cleared parasitemia in treated mice at
extremely low doses (130 mg/kg). Through this process, we have
identified that salinosporamide A represents a new class of
antimalarial drugs, which have the benefit of already proceeding
to phase I clinical trial.
Results
Screening inhibitors by parasite proliferation assays in P.
falciparum
Parasite proliferation assays were done in 96 well plates using
the DNA intercalating fluorescent dye, SYBR Green [23,24].
Using this technique, we measured the increase of parasite DNA
contained in human red blood cells after 72 hours of incubation
with our microbial extracts. Extracts were tested at three initial
concentrations: 1 mg/ml, 10 mg/ml and 100 mg/ml. Five crude
extracts showed a 50 to 100% inhibition effect at 1 mg/ml per ml
(Data not shown). The most active fraction was further selected
and identified to be the marine actinomycete, Salinispora tropica.
The most active compound of S. tropica, salinosporamide A, had
previously exhibited significant cytotoxic activity against human
tumor cells lines [16,17,18,19]. We then further tested the in vitro
effect of salinosporamide A, which showed an IC50 value against
parasite growth at 11.461.9 nM (Figure 1). This result falls within
the previously reported IC50 range of chloroquine, mefloquine and
artemisinin under our culture conditions (Figure 1). These initial
results validate our assay and the efficacy of this new natural
compound against Plasmodium in vitro.
In order to establish a baseline for proteasome inhibition and
the effect on parasite growth, we tested the commercially available
inhibitor MG-132 and found that this specific proteasome
inhibitor arrests parasite growth with an IC50 value of 4064.8
nM (Figure 1).
Parasite phenotypic analysis in presence of
salinosporamide A
In order to investigate the most efficient erythrocytic stage of
action of salinosporamide A against the parasite cell cycle, we
proceeded to a phenotypic analysis of the treated and non-treated
cultures at the three main stages of the parasite intra-erythrocytic
cycle. Parasites were synchronized using sorbitol treatment and
then incubated with the IC80 concentration (120 nM) of
salinosporamide A at the ring, trophozoite and/or schizont stages.
Parasites phenotypes were analyzed under light microscopy every
6 or 12 hours. After 6 hours in the ring stage of incubation with
the drug, parasites were clearly arrested in their cell cycle
progression when compared to the untreated cultures
(Figure 2A). After 36 to 48 hours of incubation, parasite incubated
with the drug showed signs of stress with no reinvasion into red
blood cells while untreated culture shows rings reemerging with a
10 fold increase in parasitemia. When the drug was added at the
trophozoite stage, parasites were arrested at a late trophozoite
stage and showed signs of stress and a decrease in parasitemia after
36 hours (Figure 2B). When the drug was added at the schizont
stage, the cell cycle progression was rapidly arrested. No parasite
rupture of red blood cells could be detected and schizonts expired
within a few hours (Figure 2C). These results demonstrate that
salinosporamide A is an extremely efficient inhibitor during the
erythrocytic stages of the malaria parasite.
Biochemical analysis of the effect of salinosporamide A in
parasite extracts
To investigate the potential mode of action of salinosporamide
A in the malaria parasite, we examined the amount of
ubiquitinated protein conjugates in parasite extracts after 6 hours
of incubation with the drug. As shown in figure 3, using an anti-
ubiquitin antibody, we demonstrate a considerable increase of
ubiquitinated protein when incubated with the drug. We obtained
a comparable increased of protein ubiquitination with the
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parasite cultures. Taken together, these data show that both of
these drugs inhibit the degradation of ubiquitin-tagged target
proteins and that the inhibition of ubiquitin conjugate degradation
by the proteasome may be responsible for the cell cycle arrest
detected by the analysis of the parasite morphologies under light
microscopy. The data presented here show that salinosporamide A
may certainly target a major player in the cell cycle control in
eukaryotic cells: the proteasome.
Activity against resistant P. falciparum strain
In order to confirm the efficacy of salinosporamide A on
divergent parasite strains, we tested the compound on a resistant P.
falciparum strain. We examined the FCB chloroquine resistant
strain and confirmed the effectiveness of salinosporamide A
against drug sensitive and drug resistant parasites (Figure 4).
Homology modeling and virtual ligand interaction
In an attempt to investigate the structure relationship of
salinosporamide A with the parasite’s proteasome, we examined
the published crystal structures of the yeast 20S proteasome core
particle in complex with salinosporamide A [25]. We identified the
amino acids of the core proteasome interacting with the compound
(Figure 5 A-amino acids highlighted in red). Using ClustalW, we
aligned and compared yeast, human and Plasmodium beta5 subunit
proteasome sequences. The catalytic domain was extremely well
conserved except for a single mutation (Y168G) between human and
Plasmodium sequences (Figure 5 A- Amino Acid highlighted in green).
Taken together, these data show that the parasite proteasome is
likely the target of salinosporamide A in Plasmodium.
Activity against rodent parasites
Based on our positive in vitro results and the favorable preclinical
properties of salinosporamide A in mice against human lymphoma
[22] we decided to test the in vivo efficacy of this drug using the
parasite mouse model, P. yoelii yoelii . The studies were carried out on
eight groups of five mice. P. yoelii was injected in mice at day one. If
viable parasites were detected in the blood smear at day two,
salinosporamide A was injected IP at two different concentrations
(13 mg/kg and 130 mg/kg) on days 2, 3 and 4. For each group,
untreated and treated mice were bled each day from the tail to
evaluate the percentage of infected red blood cells. Percentage of
parasitemia was monitored by microscopic observation of fixed
giemsa stained blood smears and further confirmed by an
independent scientist using flow cytometry analysis (See Materials
and Methods for further details). The study was terminated on day 5
when control mice had reached a high parasitemia in the blood
(above 60%). Our results clearly show a rapid and significant
decrease (t-test, p=7.9 E-04) of the parasitemia (5.5 fold decreased)
when treated at 130 mg/kg (Figure 6A). We then wanted to test the
efficacy of Salinosporamide A when injected subcutaneously at one
single concentration (130 mg/kg) of dose on day 1, 2 and 4. Using
this method, parasites never managed to replicate actively when
compared to the control group (t-test, p=1.9 E-05) (Figure 6B). To
furtherexaminetheoralactivityofSalinosporamideA,infectedmice
were treated by oral route at 130 mg/kg and 250 mg/kg on day 1, 2
and 4 (Figure 6C). At 130 mg/kg no significant decrease was
observed under our experimental conditions. However at 250 mg/
kg, a two-fold parasitemia decrease was observed when compared to
the control group (t-test, p=0.06). Using the three independent
administration methods, we show that Salinosporamide A can be
considerably effective in vivo.
Discussion
Marine actinomycetes are recognized as a rich source of
secondary metabolites with activities against cancer. In this study,
we have shown that extracts from ocean sediment derived
microorganisms also provide a good source for the discovery of
small molecules with antimalarial activity. We have demonstrated
that the pure compound salinosporamide A, isolated from the
Figure 1. Inhibition of P. falciparum growth by proteasome inhibitors and standard antimalarial drugs with their chemical
structures. IC50 values of parasite treated with the drug were determined using the SYBR Green assay and calculated by non linear regression using
four-parameter logistic curves on SigmaPlot 10.0 software (values are mean6standard error of the mean). Each value in the curve is the average of 2
different experiments6standard deviation. Salinosporamide A inhibited the proliferation of the parasite at a low nanomolar range (IC50=11.461.9
nM) suggesting that the compound is as efficient as standard antimalarials (e.g. chloroquine (2.360.15 nM), mefloquine (3.962.7 nM) and artemisinin
(11.768.7 nM). The inhibitor MG-132 is also a potent inhibitor of the parasites growth in vitro (IC50 of 4064.8 nM) suggesting a strong inhibition effect
of general proteasome inhibitors. Correlation coefficients (R values-factor of regression calculated by SigmaPlot 10.0) were 0.9887 for Sal A, 0.9996 for
chloroquine, 0.9989 for mefloquine, 0.9900 for artemisinin and 0.9962 for MG-132.
doi:10.1371/journal.pone.0002335.g001
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of the human malaria parasite in vitro and in vivo. Salinosporamide
A, related to the known proteasome inhibitor omuralide [26], was
later shown to be a potent inhibitor against human multiple
myeloma [22]. The specific inhibition was due to the ability of the
atypical fused d-lactam-b-lactone ring structure of salinosporamide
A to bind covalently to the active threonine site of the 20 S
proteasome subunit [16,27].
The ubiquitin/proteasome system (UPS) is known to mediate
intracellular protein degradation for misfolded, damaged and key
regulatory proteins involved in various essential cellular functions
such as transcription, stress response, cell cycle, cell differentiation
and DNA repair [28]. The UPS involves the labeling of key target
proteins with a small regulatory protein, ubiquitin, via a cascade of
three enzymes termed E1, ubiquitin-activating enzyme; E2,
ubiquitin-conjugating enzyme; and E3, ubiquitin-ligase. Once
poly-ubiquitinated, target proteins are degraded by the protea-
some complex. The importance of the UPS has been widely
illustrated by the fact that protein abnormalities in this pathway
are implicated in the pathogenesis of many human diseases,
including cancer and neurodegenerative diseases such as Alzhei-
mers or Parkinsons. Targeting the proteasome system has a huge
therapeutic implication as it can restrain growth and survival of
most cell types. The limited toxicity of proteasome inhibitors
results from the fact that rapidly dividing cells are more sensitive to
the inhibitor than non-dividing cells. Recent pre-clinical and
clinical studies validated the 20S proteasome as an excellent
therapeutic target. The outcome of these studies resulted in the
FDA approval of the first proteasome inhibitor, Bortezomib
(VelcadeH) for the treatment of refractory multiple myeloma in
2003 [29]. Comparative genomic analysis against 13 different
eukaryotic genomes identified all components of this system in
apicomplexan parasites including five Plasmodium species (Ponts N.
et al. 2008 Manuscript submitted). Partially conserved sequences
of the proteasome subunits across species, as well as the
exponential growth of the parasite in red blood cells, suggest that
the proteasome is the probable target of salinosporamide A in the
malaria parasite. Its inhibitory effect with an IC50 of 11.4 nM is as
efficient as the majority of conventional antimalarials such as
chloroquine or artemisinin (Figure 1). It is also interesting to note
that chloroquine resistant strains are still sensitive to salinospor-
amide A (Figure 4). Previous studies have demonstrated develop-
Figure 2. Effect of salinosporamide A on parasite morphology. Parasites were synchronized twice using sorbitol method. Salinosporamide A
was added at the IC80 to ring (A), trophozoite (B) or schizont (C) stage. Morphological changes were observed every 6 or 12 hours by microscopic
examination.
doi:10.1371/journal.pone.0002335.g002
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lactacystin or bortezomib related compounds (MLN-273) on
diverse apicomplexan parasites at different stages of their life cycle
[30,31,32,33,34]. The IC50 value of 40 nM of the well-defined
proteasome inhibitor MG-132 only strengthens the validity that
proteasome inhibitors are efficient against parasite growth in vitro.
In eukaryotic cells, the proteasome is known to control key
regulatory proteins involved in G1/S and M checkpoints of the
cell cycle. Progression of the erythrocytic cell cycle in Plasmodium is
poorly understood. Several key regulatory proteins such as CDK/
cyclin, which are known to be targets of the proteasome in
eukaryotes, have been identified and characterized in Plasmodium
but the mechanisms by which they are regulated, are largely
unknown. Microscopic analysis of treated P. falciparum clearly
showed an arrest of the cell cycle progression at the ring and
schizont stage before DNA synthesis and at the time parasites
rupture their red blood cells, respectively. These effects were
observed with lactacystin treatment and corroborate with the
parasite proteasome to control the erythrocytic cycle progression
before and after the DNA synthesis (S phase). The exact mode of
action by which salinosporamide A inhibits Plasmodium erythro-
cytic development is not known. However, the increased detection
of parasite ubiquitin protein conjugates after 6 hours of incubation
with the drug when compared to untreated cultures validates the
likely inhibition of the Plasmodium proteasome complex. It is
therefore expected that the inhibition effect of salinosporamide A
results from the regulation of key cell cycle proteins within the
parasite. In addition, comparative proteasome sequence analysis
and crystal structure modeling further validate the parasite
proteasome as the potential target.
In agreement with the in vitro data, salinosporamide A inhibits
parasite growth in vivo at a very low dose (130 mg/kg). This result
has been validated using three independent modes of drug
administration in separate groups of mice. Assessment of the drug
administration in mice or other model organisms will need to be
developed more carefully. This orally active compound is now
being evaluated for phase I trials at Nereus Pharmaceuticals for
the treatment of refractory multiple myeloma. Dosage is in the 150
to 500 mg/kg range. The safety profile of this compound and its
appropriate formulation will need to be further evaluated for its
potential to treat malaria.
Conclusions
Today, the urgent need for new antimalarials requires the
discovery of small and inexpensive molecules. Using a SYBR Green
bioassay on the parasite’s erythrocytic stages we have determined
that a secondary metabolite produced by a marine bacterium has
significant antimalarial activity. This finding demonstrates that
natural products remain one of the most important sources of
medicines against the parasite. The pure compound, salinospor-
amide A, was tested for its inhibitory activity against parasite
development in vitro (P. falciparum) and in vivo (P. yoelii). Our
biochemical and structural-based analyses are consistent with the
parasite 20S proteasome being the molecular target. The divergence
observed at the structural level facilitates the discovery of an
increased specificity of Plasmodium proteasome inhibitors. We are
Figure 3. Inhibition effect of salinosporamide A on chloroquine
resistant P. falciparum strain FCB. IC50 values of parasite treated
with the drug were determined using the SYBR Green assay. Each value
in the curve is the average of 2 different experiments6standard
deviation. Salinosporamide A inhibited the proliferation of the FCB
strain suggesting that the compound is equally active against drug
resistant parasites. IC50 values with Salinosporamide A were 11.4
nM61.9 for 3D7 (R=0.9887) and 19.6 nM61.4 for FCB (R=0.9990).
Chloroquine IC50 values were 2.3 nM60.15 (R=0.9996) and 64.1
nM64.7 (R=0.9964) for 3D7 and FCB respectively.
doi:10.1371/journal.pone.0002335.g003
Figure 4. Western blot analysis of parasite proteins using anti-
ubiquitin antibodies. Synchronized 3D7 parasite cultures were
treated with the IC80 value of salinosporamide A (line 2) or MG-132
(Line 3). Following parasite treatment with the drug, parasite extracts
were analyzed for the presence of ubiquitin-conjugates. Ubiquitinated
proteins accumulate in the drugs treated when compared to the
untreated cultures.
doi:10.1371/journal.pone.0002335.g004
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more potent and selective malarial proteasome inhibitor.
Materials and Methods
Preparation of the natural product extracts and pure
compound
Eight strains of diverse, Gram-positive marine bacteria weregrown
in 5 liter culture, extracted with ethyl acetate, and the extracts
concentrated and separated into nine fractions by normal phase silica
chromatography using a solvent gradient from 100% iso-octane to
10% methanol in ethyl acetate. Each crude extract and correspond-
ing setofnine fractions(10samplestotalper strain)wereconcentrated
to dryness, weighed, brought to a standard concentration of 25 mg/
ml in DMSO, and dispensed (10 ml) into 96-well microtiter plates.
Salinosporamide A was purified from a large-scale culture of
Salinispora tropica strain CNB-392 as previously described [16].
Cultivation of P. falciparum
P. falciparum malaria parasites (3D7 and FCB strains MR4/
ATCC, Manassas,VA) were cultured in human type O+
erythrocytes as previously described [35]. Synchrony was achieved
through sorbitol lysis of mature forms [36].
SYBR Green based parasite proliferation assay
Compounds were diluted in complete medium and 40 ml
transferred to 96-well assay plates (Costar #3094, Corning, NY).
To this solution, 80 ml of complete media with 3D7 infected
erythrocytes were dispensed at 2.5% hematocrit and 0.5%
parasitemia in the assay. Uninfected erythrocytes were dispensed
into the background wells at the same final hematocrit. Plates were
incubated for 72 hours in a low oxygen environment (96% N2,3 %
CO2,1 %O 2) in a modular incubation chamber (Billups-
Rothenberg, Del Mar, CA). The plates were sealed and placed
in a 280uC freezer overnight then thawed and 120 ml of lysis
buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.08% Triton X-
100, (Promega), 0.008% saponin (Acros)) with 0.2 ml/ml Sybr
Green I (Invitrogen) was dispensed into each well and incubated at
37uC in the dark for 6 hours to achieve an optimum signal to noise
ratio. The plates were read with a Molecular Devices
SpectraMAX Gemini EM at ex: 495 nm, em: 525 nm with
515 nm cut-off.
Microscopic analysis
Thin smears of malaria culture were stained with giemsa and
observed with a Nikon Eclipse E200 microscope. Images were
captured with by a Cannon EOS Rebel XT camera mounted on
an Olympus Bx51 microscope through a 60x/1.4 N.A. oil
objective utilizing Digital Photo Professional software. (Courtesy
of Morris Maduro lab.)
Western blot analysis
Synchronized cultures were grown in parallel in the presence of
140 nM salinosporamide A, 400 nM MG-132 (Calbiochem) or no
drug (control) added at the mid-trophozoite stage. After 8 hours
incubation cultures were collected, washed with PBS and the
parasites extracted by 0.15% saponin lysis (Acros). Subsequent
washes were performed in PBS supplemented with 20 mM NEM
(Pierce), 0.05 mM EDTA (Promega), 1 mM AEBSF (Fisher
Bioreagents), 0.02% Sodium Azide and Protease Inhibitor
Cocktail (Complete, Roche). Proteins were extracted from parasite
pellets through sonication in lysis buffer (50 mM TRIS-HCl,
pH 7.5 (Promega), 150 mM NaCl, 2 mM AEBSF (Fisher),
20 mM NEM (Pierce), 0.5 mM EDTA, 1% Triton X-100
(Promega), Protease Inhibitor Cocktail (Complete, Roche),
0.02% Na Azide). Proteins were separated by SDSPAGE with a
BioRad mini PROTEAN 3 cell and transferred to Invitrogen
PVDF membranes with an Owl Panther semidry electroblotter.
Blots were probed with Upstate anti-ubiquitin polyclonal antibody
and goat anti-mouse HRP secondary (Pierce) and visualized with
Amersham ECL western blotting substrate.
Homology modeling
Human, yeast and P. falciparum subunit beta-5 sequences
were aligned using ClustalW. The published crystal structure of
the yeast proteosome in complex with salinosporamide A [25]
was examined and the residues proximal to the inhibitor binding
site were identified. Substitutions identified were subsequently
considered for the possible effect on inhibitor binding between
species.
In vivo Studies
Swiss-Webster female mice weighing 25–30 grams (Hilltop Lab
Animals, Scottdale, PA) were inoculated intraperitoneal (IP) with
5610
6 P. yoelii (yoelii yoelii) parasites and separated into three
groups of five mice (day 1). On days 2 (24 hours after parasite
challenged) through 4 groups were treated by IP injection of
Figure 5. (A) Sequence alignment of the catalytic domain of the b5
subunit 20 S proteasome from yeast, human and Plasmodium obtained
with the ClustalW program. (B) Crystal structure of Salinosporamide A
interacting with the yeast 20S proteasome. Tyr168 is shown in orange
to indicate the site of the Y168G mutation in P. falciparum.
doi:10.1371/journal.pone.0002335.g005
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0 mg/kg (using a volume of 100 ml for each concentration) or days
1, 2 and 4 by oral route at 250 mg/kg, 130 mg/kg and 0 mg/kg. In
a third experiment two groups of five mice were challenge on days
1, 2 and 4 by subcutaneous injection of salinosporamide A at
130 mg/kg and 0 mg/kg. [Salinosporamide A was made fresh on
treatment days, dissolved in 100% DMSO and serially diluted
with 5% Solutol (Solutol HS 15; polyethylene glycol 660 12-
hydroxystearate; BASF, Shrevport, LA) yielding a final concen-
tration of 2% DMSO. The vehicle control (0 mg/kg) consisted of
2% DMSO and 98% (5% solutol) [22]]. Parasitemia was traced
daily by light microscopic analysis of giemsa stained thin smears
and confirmed by flow cytometry analysis. Blood samples of 4 mL
were collected and fixed in 1mL of 0.25% glutaraldehyde
(Polysciences) in PBS (pH 7.4), stained with Hoechst 33342
(Invitrogen Molecular Probes), and the average of 20,000 events
collected on a Becton Dickson FACSAria.
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